9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Condition(s):Relapsing Multiple SclerosisLast Updated:July 27, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Relapsing Multiple SclerosisLast Updated:July 27, 2021Unknown status
Condition(s):B-Cell LymphomasLast Updated:May 26, 2021Completed
Condition(s):Relapsing Forms of Multiple SclerosisLast Updated:March 25, 2024Recruiting
Condition(s):Non-Hodgkin’s LymphomaLast Updated:February 10, 2023Completed
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:May 6, 2022Completed
Condition(s):Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Low-Grade; Lymphoma, Intermediate-GradeLast Updated:October 12, 2015Withdrawn
Condition(s):Leukemia; LymphomaLast Updated:March 7, 2024Active, not recruiting
Condition(s):Nephrotic SyndromeLast Updated:July 29, 2020Terminated
Condition(s):Chronic Lymphocytic Leukemia (CLL); Leukaemia, Lymphocytic, ChronicLast Updated:January 19, 2017Completed
Condition(s):Relapse Remitting Multiple SclerosisLast Updated:February 2, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.